THE WOODLANDS, Texas, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the second quarter ended June 30, 2017.
Financial Results
Net loss for the three month period ended June 30, 2017, was ($2.2) million or ($0.08) per share as compared to a net loss of ($4.3) million or ($0.18) per share for the same period in 2016. The decreased loss for the three month period ended June 30, 2017, as compared to the same period in the prior year, was primarily due to decreased clinical development expenses related to the Company’s Proellex® and enclomiphene product candidates, as well as decreased R&D payroll and benefits expenses and legal expenses. The Company recorded, in other expense, a change in fair value of the warrant liability for the three month period ended June 30, 2017 in the amount of $160,000, which partially offset the above-described decreases.
